Do India’s compulsory licences violate TRIPs?
The compulsory licence issued to Natco over Bayer’s Nexavar drug in India and Novartis’s case at the Supreme Court could set a precedent for developing countries’ approach to pharma patents. Peter Roderick and Pravin Anand take contrasting positions on the cases
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
